



Atty. Dkt. No. 072121-0363

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Eleni VENETSANAKOS
Title: METHODS FOR TREATING CANCER USING PORIMIN AS A TARGET
Appl. No.: 10/720,696
Filing Date: 11/25/2003
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
PO Box 1450
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.



TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicant respectfully requests that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date March 29, 2004

By Richard C. Peet

FOLEY & LARDNER LLP
Customer Number: 27476
Telephone: (202) 672-5483
Facsimile: (202) 672-5399

Richard C. Peet
Attorney for Applicant
Registration No. 35,792

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/720,696
				Filing Date	11/25/2003
				First Named Inventor	Eleni VENETSANAKOS
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	3	Attorney Docket Number	072121-0363

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A11	HELL et al., "Hodgkin Cells Accumulate mRNA for <i>bcl-2</i> ," <u>Laboratory Investigation</u> , October 1995, pp. 492-496, Vol. 73, No. 4, The United States and Canadian Academy of Pathology, Inc., USA	
	A12	JANG et al., "An examination of the effects of hypoxia, acidosis, and glucose starvation on the expression of metastasis-associated genes in murine tumor cells," <u>Clin. Exp. Metastasis</u> , September 1997, pp. 469-483, Vol. 15, No. 5, Rapid Science Publishers	
	A13	LÉVESQUE et al., "PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematopoiesis," <u>Immunity</u> , September 1999, pp. 369-378, Vol. 11, No. 3, Cell Press	
	A14	LIGTENBERG et al., "Suppression of Cellular Aggregation by High Levels of Episialin," <u>Cancer Research</u> , April 15, 1992, pp. 2318-2324, Vol. 52, No. 8	
	A15	MA et al., "Molecular cloning of Porimin, a novel cell surface receptor mediating oncotic cell death," <u>PNAS</u> , August 14, 2001, pp. 9778-9783, Vol. 98, No. 17	
	A16	MANJUNATH et al., "Negative regulation of T-cell adhesion and activation by CD43," <u>Nature</u> , October 12, 1995, pp. 535-538, Vol. 377	
	A17	McCLEAN et al., "Evidence of Post-translational Regulation of P-Glycoprotein Associated with the Expression of a Distinctive Multiple Drug-resistant Phenotype in Chinese Hamster Ovary Cells," <u>Eur. J. Cancer</u> , 1993, pp. 2243-2248, Vol. 29A, No. 16, Pergamon Press Ltd.	
	A18	OSTBERG et al., "The Roman god Janus: a paradigm for the function of CD43," <u>Immunology Today</u> , December 1998, pp. 546-550, Vol. 19, No. 12	
	A19	POWELL et al., "Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype," <u>Pharmacogenetics</u> , October 1998, pp. 41-421, Vol. 8, No. 5, Lippincott Williams & Wilkins	
	A20	SHANTZ et al., "Translational regulation of ornithine decarboxylase and other enzymes of the polyamine pathway," <u>The International Journal of Biochemistry & Cell Biology</u> , 1999, pp. 107-122, Vol. 31, Elsevier Science Ltd.	
	A21	VALLEJO et al., "Evidence of tissue-specific, post-transcriptional regulation of NRF-2 expression," <u>Biochimie</u> , 2000, pp. 1129-1133, Vol. 82	
	A22	ZANNETTINO et al., "The Sialomucin CD164 (MGC-24v) Is an Adhesive Glycoprotein Expressed by Human Hematopoietic Progenitors and Bone Marrow Stromal Cells That Serves as a Potent Negative Regulator of Hematopoiesis," <u>Blood</u> , October 15, 1998, pp. 2613-2628, Vol. 92, No. 8, The American Society of Hematology	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/720,696</td> </tr> <tr> <td>Filing Date</td> <td>11/25/2003</td> </tr> <tr> <td>First Named Inventor</td> <td>Eleni VENETSANAKOS</td> </tr> <tr> <td>Group Art Unit</td> <td>Unknown</td> </tr> <tr> <td>Examiner Name</td> <td>Unknown</td> </tr> <tr> <td>Attorney Docket Number</td> <td>072121-0363</td> </tr> </table>		Application Number	10/720,696	Filing Date	11/25/2003	First Named Inventor	Eleni VENETSANAKOS	Group Art Unit	Unknown	Examiner Name	Unknown	Attorney Docket Number	072121-0363
Application Number	10/720,696																
Filing Date	11/25/2003																
First Named Inventor	Eleni VENETSANAKOS																
Group Art Unit	Unknown																
Examiner Name	Unknown																
Attorney Docket Number	072121-0363																
Sheet	1	of	3														



FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A1	WO	00/73452	A2	GENENTECH, INC.	12-07-2000		
	A2	WO	01/32837	A1	HUMAN GENOME SCIENCES, INC.	05-10-2001		
	A3	EP	1 067 182	A2	HELIX RESEARCH INSTITUTE	01-10-2001		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A4	ALBERTS, <u>Molecular Cell Biology</u> , 3 rd Edition, 1998, p. 465, Scientific American Books, Inc., USA	
	A5	BAŽIL et al., "Apoptosis of Human Hematopoietic Progenitor Cells Induced by Crosslinking of Surface CD43, the Major Sialoglycoprotein of Leukocytes," <u>Blood</u> , July 15, 1995, pp. 502-511, Vol. 86, No. 2, W.B. Saunders Company	
	A6	BRENNAN et al., "Cytokine Production in Culture by Cells Isolated from the Synovial Membrane," <u>Journal of Autoimmunity</u> , June 1989, pp. 177-189, Vol. 2 (Supplement), Academic Press	
	A7	CARRÈRE et al., "Immunoreactive pancreatic Reg protein in sera from cystic fibrosis patients with and without pancreatic insufficiency," <u>Gut</u> , April 1999, pp. 545-551, Vol. 44, No. 4, BMJ Publishing	
	A8	ERIKSSON et al., "Insulin resistance in Type 2 (non-insulin-dependent) diabetic patients and their relatives is not associated with a defect in the expression of the insulin-responsive glucose transporter (GLUT-4) gene in human skeletal muscle," <u>Diabetologia</u> , February 1992, pp. 143-147, Vol. 35, No. 2, Springer-Verlag	
	A9	FU et al., "Translational regulation of human p53 gene expression," <u>The EMBO Journal</u> , 1996, pp. 4392-4401, Vol. 15, No. 16, Oxford University Press	
	A10	GUO et al., "Induction Profile of Rat Organic Anion Transporting Polypeptide 2 (oatp2) by Prototypical Drug-Metabolizing Enzyme Inducers That Activate Gene Expression through Ligand-Activated Transcription Factor Pathways," <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 2002, pp. 206-212, Vol. 300, No. 1, The American Society for Pharmacology and Experimental Therapeutics, USA	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/720,696
				Filing Date	11/25/2003
				First Named Inventor	Eleni VENETSANAKOS
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	of	3	Attorney Docket Number	072121-0363

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.